아르보바이러스 감염 시장 : 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• The arbovirus Infection market is projected to grow steadily during the forecast period (2025-2034), driven by the expanding geographic range of vector species, climate change increasing vector breeding seasons, urbanization leading to higher human-vector contact, and the emergence of new arboviral strains that challenge existing public health measures.
• Rising arbovirus infections are fueled by climate change expanding mosquito habitats, booming urban populations creating ideal breeding grounds, and global travel rapidly introducing viruses to new regions. This perfect storm has turned once-localized threats into global health challenges.
• Arbovirus infection management hinges on swift supportive care and symptom control, guided by disease severity and patient risk factors. Mild cases benefit from outpatient monitoring and hydration, while severe or neuroinvasive presentations demand hospitalization and specialized interventions. Treatment is tailored based on diagnostic findings, with a lack of improvement flagging potential complications or the need for advanced therapies.
• The current arbovirus infection landscape is competitive, with multiple approved treatment options, including IXCHIQ (vla1553), VIMKUNYA (Chikungunya Vaccine, Recombinant), and QDENGA (tak-003), among others.
• The fight against arbovirus infection remains challenged by vector resistance, scarce antivirals, diagnostic delays, emerging strains, and vaccine gaps, underscoring the need for next-gen vaccines, novel therapies, and advanced surveillance.
• The emerging pipeline for arbovirus infections features candidates such as SP0218/vYF and other investigational agents, reflecting growing R&D interest driven by the rising global incidence and potential outbreak risks.
• Sanofi's SP0218 is poised to be a pioneer among emerging therapies, with Phase III data expected in the second half of 2026, potentially strengthening its role in addressing the unmet needs of arbovirus infections.

DelveInsight's comprehensive report titled "Arbovirus Infection - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of arbovirus Infection. The report presents historical and projected epidemiological data covering arthropods-specific incident cases of arbovirus infection, total incident cases of arbovirus infection and treated cases of arbovirus infection. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in arbovirus Infection. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Arbovirus Infection Overview

Arbovirus infection refers to illness caused by viruses transmitted through arthropod vectors like mosquitoes and ticks, with dengue, chikungunya, and Zika being the most prominent. These infections often present suddenly with high fever, headache, muscle and joint pain, rash, and sometimes gastrointestinal symptoms such as nausea or vomiting. In severe cases, arboviruses can directly or indirectly damage the kidneys, leading to complications like acute kidney injury, proteinuria, or hematuria-particularly in individuals with pre-existing kidney issues, advanced age, or compromised immunity.

Examples of arboviral infections include dengue fever, Zika virus disease, chikungunya, west nile virus infection, japanese encephalitis, and yellow fever, each varying in severity, geographic distribution, and potential for complications. These diseases are prevalent in tropical and subtropical regions but can also occur in temperate areas during outbreaks.

Symptoms can escalate rapidly, with warning signs including persistent vomiting, severe abdominal pain, reduced urine output, or swelling, and may progress to multi-organ involvement if not managed promptly. Early recognition and supportive care are critical, as there are no specific antiviral treatments for most arboviral infections; management focuses on hydration, pain and fever control, and monitoring for complications, especially in high-risk populations.

Arbovirus Infection Diagnosis and Treatment Algorithm

Diagnosing arbovirus infection involves assessing both clinical symptoms and laboratory evidence. Physicians look for signs such as sudden high fever, severe headache, muscle or joint pain, and rash-particularly in individuals with recent exposure to mosquitoes or ticks or travel to endemic regions. Laboratory confirmation is achieved through tests like RT-PCR to detect viral RNA or serology to identify specific antibodies, helping to distinguish arboviral infections from other febrile illnesses and ensuring accurate diagnosis for timely management.

Laboratory diagnosis of arbovirus infection typically involves blood tests that may reveal low white blood cell and platelet counts, as well as elevated liver enzymes or inflammatory markers. Serological assays and molecular tests, such as RT-PCR, are essential to confirm the specific viral cause and guide clinical management. In severe or atypical cases, imaging like ultrasound or MRI may be used to assess organ involvement or complications. Timely and precise diagnosis is vital to ensure appropriate supportive care and prevent serious outcomes.

Treatment of arbovirus infection focuses on supportive care, as there are no specific antiviral therapies for most arboviruses. Mild cases are managed with rest, adequate hydration, and medications like acetaminophen to control fever and pain-NSAIDs are generally avoided due to bleeding risks, especially in dengue. For severe presentations, hospitalization may be needed for intravenous fluids, close monitoring, and management of complications such as shock or organ involvement. Patient education about warning signs and the importance of follow-up is essential to prevent deterioration and ensure optimal recovery.

Arbovirus Infection Epidemiology

The epidemiology section of the arbovirus infection market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of arbovirus Infection. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

In the US, according to the Pan American Health Organization (PAHO), the reported dengue incidence was 220.0 cases per 100,000 population. This figure highlights the continued public health burden of dengue across the region, underscoring the need for effective prevention and control measures.

West Nile virus (WNV) was the predominant domestic arboviral disease reported in the US, representing 95% of all cases. The incidence of WNV neuroinvasive disease in the US stood at 0.53 cases per 100,000.

In Italy, the reported incidence of Tick-Borne Encephalitis (TBE) was found to be 5.95 cases per 100,000 population.

The epidemiology of arbovirus infection is expected to change during the forecast period (2025-2034).

Arbovirus Infection Market Outlook

The arbovirus infection therapeutics market is further expected to increase by the major drivers, such as the rising incidence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

Bavarian Nordic achieved a significant milestone in 2025 with VIMKUNYA, the world's first approved chikungunya vaccine for individuals aged 12 years and older, securing regulatory approvals across the US, EU, and UK within a short span. Following the US FDA and European Commission authorizations in February, the company swiftly launched the vaccine commercially in the US by March, targeting travel clinics and healthcare providers, and gained MHRA approval in May. This rapid, multi-region rollout not only positions VIMKUNYA to address a long-standing unmet need in arbovirus prevention but also strengthens Bavarian Nordic's foothold in the travel vaccine market, with potential spillover demand from endemic regions.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the arbovirus infection market in the 7MM is expected to change significantly during the study period 2020-2034.

Arbovirus Infection Drug Chapters

Marketed Arbovirus Infection Drugs

VIMKUNYA (Chikungunya Vaccine, Recombinant): Bavarian Nordic

VIMKUNYA the first and only virus-like particle (VLP) vaccine for chikungunya prevention in individuals aged 12 and older, offers a single-dose, prefilled syringe formulation designed to induce strong CHIKV-specific immune responses, with protection beginning as early as one week. Approved under accelerated approval based on neutralizing antibody levels, its continued authorization depends on confirmatory trial outcomes. Being non-infectious and free of viral genetic material, it provides a safe option for broad population use in mitigating the growing burden of chikungunya.

IXCHIQ (VLA1553): Valneva

IXCHIQ is a chikungunya vaccine developed by Valneva. It is a live-attenuated, single-dose vaccine administered by intramuscular injection and is indicated for individuals at higher risk of exposure to the chikungunya virus. The vaccine is intended to prevent disease caused by chikungunya virus (CHIKV), although its exact mechanism of protection has not yet been fully established. IXCHIQ stimulates CHIKV-specific immune responses.

IXCHIQ is approved in Europe for preventing disease caused by the Chikungunya virus in individuals aged 12 years and older. In the US and the UK, approval is currently for those aged 18 and above. Regulatory authorities in both countries are reviewing applications to potentially extend the approval to include adolescents aged 12-17 years.

QDENGA (TAK-003): Takeda Pharmaceutical

QDENGA is a live-attenuated dengue vaccine built on a dengue serotype 2 backbone engineered to protect against all four virus serotypes. Approved in EU Member States for individuals aged four and older, it is administered subcutaneously as a 0.5 mL dose in a two-dose schedule at 0 and 3 months, following official recommendations to optimize protection against dengue.

In December 2022, the European Commission approved QDENGA for marketing in the European Union for the prevention of dengue in individuals aged four years and older.

In July 2023, Takeda voluntarily withdrew its US Biologics License Application (BLA) for the dengue vaccine candidate QDENGA (TAK-003). This decision came after consultations with the US FDA, which identified issues related to data collection that could not be addressed within the current review cycle.

Emerging Arbovirus Infection Drugs

The emerging pipeline for arbovirus infections features candidates such as SP0218, and others, reflecting growing R&D focus on strengthening prevention and control strategies for these vector-borne diseases. This trend underscores increasing investment in next-generation vaccines aimed at addressing gaps in efficacy, supply, and global accessibility.

SP0218/vYF: Sanofi

SP0218, developed by Sanofi, is a next-generation live attenuated yellow fever vaccine, freeze-dried and produced in Vero cells, for subcutaneous or intramuscular use in individuals aged nine months and above. Positioned to replace STAMARIL and YF-VAX, it aims to secure a sustainable and reliable global supply through a single, streamlined product.

The drug is currently in a Phase III clinical trial, with data readout anticipated in the second half of 2026.

Arbovirus Infection Market Segmentation

DelveInsight's 'Arbovirus Infection - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future arbovirus infection market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Arbovirus Infection Market Size by Countries

The arbovirus infection market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) arbovirus infection market, primarily attributed to the country's higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Arbovirus Infection Market Size by Therapies

Arbovirus Infection Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034.

Arbovirus Infection Drugs Uptake

This section focuses on the sales uptake of potential arbovirus infection drugs that have recently been launched or are anticipated to be launched in the arbovirus infection market between 2020 and 2034. It estimates the market penetration of arbovirus infection drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the arbovirus infection market.

The emerging arbovirus infection therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the arbovirus infection market.

Arbovirus Infection Market Access and Reimbursement

DelveInsight's 'Arbovirus Infection - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of arbovirus Infection.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current arbovirus infection market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the arbovirus infection domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or arbovirus infection market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the arbovirus infection unmet needs.

Arbovirus Infection: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the University of Colorado School of Medicine, US; Oxford, UK; Academie Nationale de Medecine, France; Bologna General Hospital, Italy; Viral Disease and Epidemiology Research Division, Japan, and others.

"Arbovirus infection is a growing global concern caused by arthropod-borne viruses, with the potential to affect multiple organ systems, including the central nervous system. These infections often present with a range of clinical features, making diagnosis challenging without a thorough evaluation of symptoms, laboratory findings, and imaging results. Early recognition is essential, as accurate identification of the specific viral cause aids in guiding patient management and informing prognosis, even in the absence of approved antiviral therapies."

"In Arbovirus infections, the persistence and spread of the virus are not solely dependent on traditional viremic transmission. Instead, arboviruses utilize a range of alternative mechanisms-such as vertical transmission, persistent infections in vectors or hosts, and nonviremic transmission between co-feeding arthropods-to maintain circulation even in the absence of overt disease. Understanding these diverse transmission strategies is essential, as it underscores the virus's ability to evade immune responses and sustain itself in complex ecological settings, informing both surveillance and control efforts."

"Arboviral infections are managed mainly through supportive care, as no broad-spectrum antivirals are approved. Management centers on hydration, fever and pain control with paracetamol or metamizole, and avoiding NSAIDs due to bleeding risks. Severe cases may require fluid resuscitation, neurological monitoring, and mechanical ventilation if encephalitis occurs. While vaccines exist for select arboviruses, most rely solely on symptomatic treatment."

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the arbovirus infection Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Arbovirus Infection Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase I, Phase II and Phase III stages and examines companies involved in developing targeted therapeutics for arbovirus infection. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging arbovirus infection therapies.

Arbovirus Infection Report Insights

• Arbovirus Infection Patient Population
• Therapeutic Approaches
• Arbovirus Infection Pipeline Analysis
• Arbovirus Infection Market Size and Trends
• Arbovirus Infection Market Opportunities
• Impact of Upcoming Therapies

Arbovirus Infection Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Arbovirus Infection Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Arbovirus Infection Market
• Arbovirus Infection Drugs Uptake

Arbovirus Infection Report Assessment

• Arbovirus Infection Current Treatment Practices
• Unmet Needs
• Arbovirus Infection Pipeline Product Profiles
• Arbovirus Infection Market Attractiveness

Key Questions:

• How common is Arbovirus Infection?
• What are the key findings of arbovirus infection epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for arbovirus infection?
• What are the disease risk, burden, and unmet needs of arbovirus infection?
• At what CAGR is the arbovirus infection market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the arbovirus infection market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of arbovirus infection in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of arbovirus infection?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the arbovirus infection market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for arbovirus infection?

The primary goals are to relieve symptoms, prevent severe complications like shock or organ failure, and support recovery through careful fluid management and monitoring, as there are no specific antiviral therapies for most arboviral diseases.

2. What are the challenges in managing arbovirus infection?

Major challenges include the absence of targeted antivirals, difficulty distinguishing arboviral infections from other febrile illnesses, risks of rapid deterioration in high-risk groups, and the need for timely supportive interventions to prevent severe outcomes.

3. What are the key factors driving the growth of the arbovirus infection market?

Rising global incidence due to climate change, urbanization, and increased travel, coupled with the urgent demand for rapid diagnostics, vaccines, and improved supportive care, are fueling market expansion and innovation.

4. How will the arbovirus infection market and epidemiology forecast report benefit the clients?

The report delivers evidence-based insights on clinical management, market trends, pipeline therapies, and evolving patient needs, empowering stakeholders to make strategic decisions and capitalize on emerging opportunities in this rapidly changing landscape.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution in 2024
• 3.2. Market Share (%) Distribution in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. Arthropods-specific Incident Cases of Arbovirus Infection
  • 8.2.2. Total Incident Cases of Arbovirus Infection
• 8.3. Total Incident Cases of Arbovirus Infection in the 7MM
• 8.4. The US
  • 8.4.1. Arthropods-specific Incident Cases of Arbovirus Infection
  • 8.4.2. Total Incident Cases of Arbovirus Infection
  • 8.4.3. Treated Cases of Arbovirus Infection
• 8.5. EU4 and the UK
  • 8.5.1. Arthropods-specific Incident Cases of Arbovirus Infection
  • 8.5.2. Total Incident Cases of Arbovirus Infection
  • 8.5.3. Treated Cases of Arbovirus Infection
• 8.6. Japan
  • 8.6.1. Arthropods-specific Incident Cases of Arbovirus Infection
  • 8.6.2. Total Incident Cases of Arbovirus Infection
  • 8.6.3. Treated Cases of Arbovirus Infection

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. VIMKUNYA (Chikungunya Vaccine, Recombinant): Bavarian Nordic
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestone
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. IXCHIQ/ (VLA1553): Valneva
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestone
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
• 10.4. QDENGA (TAK-003): Takeda Pharmaceutical
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestone
  • 10.4.3. Other Development Activities
  • 10.4.4. Clinical Trials Information
  • 10.4.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. SP0218/vYF: Sanofi
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views

12. Arbovirus Infection: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Arbovirus Infection in the 7MM
• 12.6. Market Size of Arbovirus Infection by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Arbovirus Infection
  • 12.7.2. Market Size of Arbovirus Infection by Therapies
• 12.8. Market Size of Arbovirus Infection in the EU4 and the UK
  • 12.8.1. Total Market Size of Arbovirus Infection
  • 12.8.2. Market Size of Arbovirus Infection by Therapies
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Arbovirus Infection
  • 12.9.2. Market Size of Arbovirus Infection by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

• 16.1. The US
  • 16.1.1. Centre for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The UK
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Abbreviations and Acronyms
• 17.2. Bibliography
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight